ETNB - NASDAQ

89bio, Inc.

ETNB·NASDAQ

$14.84

+0.0000%

HealthcareBiotechnology

89bio, Inc., a clinical-stage biopharmaceutical company, focuses on the development and commercialization of therapies for the treatment of liver and cardio-metabolic diseases. Its lead product candidate is pegozafermin, a glycoPEGylated analog of fibroblast growth factor 21 for the treatment of nonalcoholic steatohepatitis. The company also intends to develop pegozafermin for the treatment of severe hypertriglyceridemia. 89bio, Inc. was incorporated in 2018 and is headquartered in San Francisco, California.

Statements Value Model

At a Glance

Live Snapshot

Market Cap$2.20B

EPS-3.5100

P/E Ratio-2.23

Earnings Date11/06/2025

No Revenue Data

ETNB has not reported any revenue values in the available annual periods.

-367.08M

Net Income

158%

3Y+307.0%

5Y+539.0%

10Y+2169.0%

-367.82M

Operating Cash Flow

185%

3Y+379.0%

5Y+1345.0%

10Y+2850.0%

89bio, Inc. Profit Bridge

ETNB · NASDAQ

Revenue & Cost of Sales

Revenue0.00

Cost of Goods Sold (38.00K)

Gross Profit-38.00K

Operating Expenses

Operating Expenses (384.66M)

Operating Income-384.66M

Other Income & Taxes

Interest Expense (3.79M)

Other Income/Expense18.27M

Pretax Income-366.39M

Income Tax (692.00K)

Net Income-367.08M

Net Income

-367.08M

Profitability Analysis

89bio, Inc. Income Statement

ETNB • NASDAQ

89bio, Inc. Income Statement	Dec 2024	Dec 2023	Dec 2022	Dec 2021	Dec 2020	Dec 2019	Dec 2018
REVENUE
GROSS PROFIT
Cost of Revenue	(38K)	(273K)	(240K)	(79K)	(60K)	(17K)	(6K)
Gross Profit	-38K	-273K	-240K	-79K	-60K	-17K	-6K
OPERATING INCOME
Operating Expenses	(384.7M)	(151.2M)	(102.2M)	(89.7M)	(49.4M)	(26.6M)	(15.2M)
Selling, General & Administrative	(39.6M)	(29M)	(21.5M)	(19.4M)	(13.2M)	(5.3M)	(1.5M)
Research & Development	(345M)	(122.2M)	(80.8M)	(70.3M)	(36.2M)	(21.3M)	(13.7M)
Operating Income	-384.7M	-151.2M	102.2M	-89.7M	-49.4M	-26.6M	-15.2M
PRE-TAX INCOME
Interest Expense	(3.8M)	(3.6M)	(1.9M)	(674K)	(0.0)	(0.0)	(0.0)
Net Interest Income	-3.8M	-3.6M	242K	-526K	0.0	0.0	0.0
Total Other Income Expenses Net	18.3M	12.9M	242K	-526K	-203K	-30.6M	-986K
Income Before Tax	-366.4M	-138.3M	-102M	-90.3M	-49.6M	-57.2M	-16.1M
NET INCOME
Income Tax Expense	(692K)	(3.9M)	(19K)	-147K	-59K	(218K)	(28K)
Net Income	-367.1M	-142.2M	-102M	-90.1M	-49.5M	-57.4M	-16.2M

SEC Filings

ETNB - Filing history and reports

No SEC filings available for ETNB

Related Guides

Blog Categories

Continue your ETNB research with focused valuation guides.

Fundamentals

Decode statement quality and operating durability.

Accounting

Interpret line items with cleaner analytical framing.

Forecasting

Translate historical performance into forward scenarios.

Reference

Use practical frameworks for statement-led valuation.

Research Paths

Pick your next lens

Snapshot

Start with context, operating signals, and key market metrics.

Value Model

Stress test fair value across bear, base, and bull assumptions.

Statements

Validate revenue quality, margins, and balance sheet durability.

Earnings Call

Read management commentary and compare it with reported outcomes.

Dividends

Check payout sustainability and long-term distribution behavior.

Analyst Expectations

Review consensus spread and where estimate risk is concentrated.